UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 42.

Kletenkov, K; Hoffmann, D; Böni, J; Yerly, S; Aubert, V; Schöni-Affolter, F; Struck, D; Verheyen, J; Klimkait, T (2017). Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? Journal of Antimicrobial Chemotherapy, 72(3):866-875.

Calmy, A; van Delden, C; Giostra, E; Junet, C; Rubbia Brandt, L; Yerly, S; Chave, J-P; Samer, C; Elkrief, L; Vionnet, J; Berney, T (2016). HIV-Positive-to-HIV-Positive Liver Transplantation. American Journal of Transplantation, 16(8):2473-2478.

Schüpbach, J; Niederhauser, C; Yerly, S; Regenass, S; Gorgievski, M; Aubert, V; Ciardo, D; Klimkait, T; Dollenmaier, G; Andreutti, C; Martinetti, G; Brandenberger, M; Gebhardt, M D (2015). Decreasing proportion of recent infections among newly diagnosed HIV-1 cases in Switzerland, 2008 to 2013 based on line-immunoassay-based algorithms. PLoS ONE, 10(7):e0131828.

Vetter, B N; Orlowski, V; Fransen, K; Niederhauser, C; Aubert, V; Brandenberger, M; Ciardo, D; Dollenmaier, G; Klimkait, T; Regenass, S; Schmid, P; Schottstedt, V; Suter-Riniker, F; Yerly, S; Shah, C; Böni, J; Schüpbach, J (2014). Generation of a Recombinant Gag Virus-Like-Particle Panel for the Evaluation of p24 Antigen Detection by Diagnostic HIV Test. PLoS ONE, 9(10):e111552-e111552.

Metzner, K J; Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Hirsch, H; Vernazza, P L; Cavassini, M; Calmy, A; Bernasconi, E; Weber, R; Gunthard, H F (2014). Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS, 28(15):2231-2239.

Kouyos, R D; Rauch, A; Braun, D L; Yang, W-L; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Shah, C; Kovari, H; Calmy, A; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Gunthard, H F (2014). Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 210(10):1555-1561.

Hasse, B; Iff, M; Ledergerber, B; Calmy, A; Schmid, P; Hauser, C; Cavassini, M; Bernasconi, E; Marzolini, C; Tarr, P E; Aubert, V; Barth, J; Battegay, M; Bernasconi, E; Boni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Egger, M; Elzi, L; Fehr, J; Fellay, J; Furrer, H; Fux, C A; Gorgievski, M; Gunthard, H; Haerry, D; Hasse, B; Hirsch, H H; Hosli, I; Kahlert, C; Kaiser, L; Keiser, O; Klimkait, T; Kouyos, R; Kovari, H; Ledergerber, B; Martinetti, G; Martinez de Tejada, B; Metzner, K; Muller, N; Nadal, D; Pantaleo, G; Rauch, A; Regenass, S; Rickenbach, M; Rudin, C; Schoni-Affolter, F; Schmid, P; Schultze, D; Schupbach, J; Speck, R; Staehelin, C; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2014). Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study. Open Forum Infectious Diseases, 1(2):ofu040.

Schüpbach, J; Gebhardt, M D; Scherrer, A U; Bisset, L R; Niederhauser, C; Regenass, S; Yerly, S; Aubert, V; Suter, F; Pfister, S; Martinetti, G; Andreutti, C; Klimkait, T; Brandenberger, M; Gunthard, H F (2013). Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. PLoS ONE, 8(8):e71662.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

Schüpbach, J; Bisset, L R; Gebhardt, M D; Regenass, S; Bürgisser, P; Gorgievski, M; Klimkait, T; Andreutti, C; Martinetti, G; Niederhauser, C; Yerly, S; Pfister, S; Schultze, D; Brandenberger, M; Schöni-Affolter, F; Scherrer, A U; Gunthard, H F (2012). Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infectious Diseases, 12(88):1471-2334.

Stadler, T; Kouyos, R; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Joos, B; Rieder, P; Xie, D; Günthard, H F; Drummond, A J; Bonhoeffer, S (2012). Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 29(1):347-357.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Scherrer, A U; von Wyl, V; Götte, M; Klimkait, T; Cellerai, C; Yerly, S; Böni, J; Held, L; Ledergerber, B; Günthard, H F (2012). Polymorphic mutations associated with the emergence of the multi-nucleoside/tide resistance mutations 69 insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes, 59(2):105-112.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Rieder, P; Joos, B; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Rauch, A; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases, 52(4):532-539.

Kouyos, R D; von Wyl, V; Hinkley, T; Petropoulos, C J; Haddad, M; Whitcomb, J M; Böni, J; Yerly, S; Cellerai, C; Klimkait, T; Günthard, H F; Bonhoeffer, S (2011). Assessing predicted HIV-1 replicative capacity in a clinical setting. PLoS Pathogens, 7(11):e1002321.

El Amari, E B; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV Medicine, 12(7):394-402.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

Schüpbach, J; Bisset, L R; Regenass, S; Bürgisser, P; Gorgievski, M; Steffen, I; Andreutti, C; Martinetti, G; Shah, C; Yerly, S; Klimkait, T; Gebhardt, M; Schöni-Affolter, F; Rickenbach, M (2011). High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease. BMC Infectious Diseases, 11(1):254.

Scherrer, A U; Ledergerber, B; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Rauch, A; Hirschel, B; Cavassini, M; Elzi, L; Vernazza, P L; Bernasconi, E; Held, L; Günthard, H F (2011). Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical Infectious Diseases, 53(11):1143-1152.

Scherrer, A U; von Wyl, V; Joos, B; Klimkait, T; Bürgisser, P; Yerly, S; Böni, J; Ledergerber, B; Günthard, H F (2011). Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. Journal of Infectious Diseases, 203(6):791-797.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

von Wyl, V; Kouyos, R D; Yerly, S; Böni, J; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Staehelin, C; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. Journal of Infectious Diseases, 204(7):1095-1103.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Schoeni-Affolter, F; Ledergerber, B; Rickenbach, M; Rudin, C; Günthard, H F; Telenti, A; Furrer, H; Yerly, S; Francioli, P (2010). Cohort profile: the Swiss HIV Cohort study. International Journal of Epidemiology, 39(5):1179-1189.

von Wyl, V; Ehteshami, M; Symons, J; Bürgisser, P; Nijhuis, M; Demeter, L M; Yerly, S; Böni, J; Klimkait, T; Schuurman, R; Ledergerber, B; Götte, M; Günthard, H F (2010). Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. Journal of Infectious Diseases, 201(7):1054-1062.

von Wyl, V; Ehteshami, M; Demeter, L M; Bürgisser, P; Nijhuis, M; Symons, J; Yerly, S; Böni, J; Klimkait, T; Schuurman, R; Ledergerber, B; Götte, M; Günthard, H F (2010). HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clinical Infectious Diseases, 51(5):620-628.

Rieder, P; Joos, B; von Wyl, V; Kuster, H; Grube, C; Leemann, C; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Weber, R; Fischer, M; Günthard, H F (2010). HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS, 24(8):1177-1183.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Alizon, S; von Wyl, V; Stadler, T; Kouyos, R D; Yerly, S; Hirschel, B; Böni, J; Shah, C; Klimkait, T; Furrer, H; Rauch, A; Vernazza, P L; Bernasconi, E; Battegay, M; Bürgisser, P; Telenti, A; Günthard, H F; Bonhoeffer, S; Swiss HIV Cohort Study (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathogens, 6(9):e1001123.

Gutmann, C; Cusini, A; Günthard, H F; Fux, C; Hirschel, B; Decosterd, L A; Cavassini, M; Yerly, S; Vernazza, P L (2010). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS, 24(15):2347-2354.

Müller, V; von Wyl, V; Yerly, S; Böni, J; Klimkait, T; Bürgisser, P; Ledergerber, B; Günthard, H F; Bonhoeffer, S (2009). African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS, 23(10):1269-1276.

Metzner, K J; Giulieri, S G; Knoepfel, S A; Rauch, P; Burgisser, P; Yerly, S; Günthard, H F; Cavassini, M (2009). Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clinical Infectious Diseases, 48(2):239-247.

Scherrer, A U; Hasse, B; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Bucher, H C; Ledergerber, B; Günthard, H F (2009). Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Medicine, 10(10):647-656.

Yerly, S; Junier, T; Gayet-Ageron, A; Amari, E B E; von Wyl, V; Günthard, H F; Hirschel, B; Zdobnov, E; Kaiser, L (2009). The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS, 23(11):1415-1423.

Gupta, R K; Hill, A; Sawyer, A W; Cozzi-Lepri, A; von Wyl, V; Yerly, S; Lima, V D; Günthard, H F; Gilks, C; Pillay, D (2009). Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, 9(7):409-447.

HIV Cohort Study, Switzerland; von Wyl, V; Yerly, S; Klimkait, T; Böni, J; Bürgisser, P; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Rickenbach, M; Ledergerber, B; Guenthard, H F (2008). Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases, 46:1299-1309.

Schüpbach, J; Gebhardt, M D; Tomasik, Z; Niederhauser, C; Yerly, S; Bürgisser, P; Matter, L; Gorgievski, M; Dubs, R; Schultze, D; Steffen, I; Andreutti, C; Martinetti, G; Güntert, B; Staub, R; Daneel, S; Vernazza, P (2007). Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Medicine, 4(12):e343.

Yerly, S; von Wyl, V; Ledergerber, B; Böni, J; Schüpbach, J; Bürgisser, P; Klimkait, T; Rickenbach, M; Kaiser, L; Günthard, H F; Perrin, L (2007). Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS, 21(16):2223-2229.

von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, P L; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, H F; Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of Internal Medicine, 167(16):1782-1790.

Schüpbach, J; Günthard, H F; Joos, B; Fischer, M B; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(3):250-256.

This list was generated on Tue Jul 25 05:03:31 2017 CEST.